Lumida
/BCRX
⌘K
BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

BCRX
$8.12USD-2.05%-0.17 today

MARKET CAP

2.1B

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $8

52W RANGE

$6
$11

AI Summary

Stalk
StalkMedium

Despite a decisive support failure on elevated volume, extreme oversold conditions have triggered mean-reversion eligibility, flipping the medium-term bias to bullish. However, short-term execution remains unfavorable as price trades below declining 9/20/50 EMAs and rejects on minor rebounds. We will stalk for a pullback into structural support around the 200-day SMA and prior consolidation lows under the Growth at Reasonable Price strategy before considering a long entry.

  • Q2 revenue rose 45% YoY to $213.9M, driven by ORLADEYO demand.
  • Consensus price target of $20.60 implies 108% upside potential.
  • Negative earnings yield and low book-to-price point to premium valuation.
Full analysis →
Insider Trades38 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
May 13, 2026SellBCRXAlane P BarnesChief Legal Officer125,000$7.29$2.1B-27.63%+35.33%$911.3K+0.00%Sell Now
Mar 16, 2026SellBCRXAlane P BarnesChief Legal Officer300,000$7.33$2.1B-27.63%+35.33%$2.2M+0.00%Sell Now
Dec 19, 2025SellBCRXAlane P BarnesChief Legal Officer38,675$7.55$2.1B-27.63%+35.33%$291.8K-4.51%Sell Now
Dec 19, 2025BuyBCRXCharles K GayerPresident and CCO85,710$5.33$2.1B-27.63%+35.33%$456.9K+1.75%Sell Now
Dec 19, 2025SellBCRXJon P StonehouseChief Executive Officer61,793$7.41$2.1B-27.63%+35.33%$457.9K-4.46%Sell Now
Dec 18, 2025SellBCRXJon P StonehouseChief Executive Officer40,000$7.29$2.1B-27.63%+35.33%$291.6K+0.00%Sell Now
Dec 12, 2025SellBCRXCharles K GayerPresident and CCO8,181$7.57$2.1B-27.63%+35.33%$61.9K-1.92%Sell Now
Dec 12, 2025SellBCRXJon P StonehouseChief Executive Officer27,368$7.57$2.1B-27.63%+35.33%$207.2K-1.91%Sell Now
Dec 12, 2025SellBCRXAlane P BarnesChief Legal Officer29,750$7.63$2.1B-27.63%+35.33%$226.9K-4.36%Sell Now
Dec 1, 2025SellBCRXAlane P BarnesChief Legal Officer252,684$5.77$2.1B-27.63%+35.33%$1.5M-4.15%Sell Now
Mar 31, 2025SellBCRXHelen M. ThackrayChief R&D Officer7,525$7.50$2.1B-27.63%+35.33%$56.4K-1.96%Sell Now
Dec 19, 2024SellBCRXAlane P BarnesChief Legal Officer2,461$7.39$2.1B-27.63%+35.33%$18.2K-0.37%Sell Now
Dec 19, 2024SellBCRXAnthony DoyleChief Financial Officer2,461$7.39$2.1B-27.63%+35.33%$18.2K-0.39%Sell Now
Dec 19, 2024SellBCRXCharles K GayerChief Commercial Officer2,461$7.39$2.1B-27.63%+35.33%$18.2K-0.36%Sell Now
Dec 19, 2024SellBCRXHelen M. ThackrayChief R&D Officer6,096$7.39$2.1B-27.63%+35.33%$45.0K-0.94%Sell Now
Dec 19, 2024SellBCRXJon P StonehousePresident & CEO54,010$1.92$2.1B-27.63%+35.33%$103.5K-0.38%Sell Now
Dec 14, 2024SellBCRXHelen M. ThackrayChief R&D Officer7,150$7.53$2.1B-27.63%+35.33%$53.8K-2.63%Sell Now
Dec 14, 2024SellBCRXAnthony DoyleChief Financial Officer7,890$7.53$2.1B-27.63%+35.33%$59.4K-2.95%Sell Now
Dec 14, 2024SellBCRXCharles K GayerChief Commercial Officer8,251$7.53$2.1B-27.63%+35.33%$62.1K-2.68%Sell Now
Dec 14, 2024SellBCRXAlane P BarnesChief Legal Officer8,613$7.53$2.1B-27.63%+35.33%$64.9K-2.84%Sell Now
Dec 14, 2024SellBCRXJon P StonehousePresident & CEO27,525$7.53$2.1B-27.63%+35.33%$207.3K-2.44%Sell Now
May 14, 2024BuyBCRXHelen M. ThackrayChief R&D Officer30,000$5.86$2.1B-27.63%+35.33%$175.8K+12.39%Sell Now
May 14, 2024BuyBCRXAnthony DoyleChief Financial Officer36,300$5.57$2.1B-27.63%+35.33%$202.2K+15.75%Sell Now
May 13, 2024BuyBCRXAlane P BarnesChief Legal Officer5,000$5.53$2.1B-27.63%+35.33%$27.6K+1.69%Sell Now
May 13, 2024BuyBCRXCharles K GayerChief Commercial Officer30,000$5.47$2.1B-27.63%+35.33%$164.1K+10.81%Sell Now
May 13, 2024BuyBCRXJon P StonehousePresident & CEO30,000$5.55$2.1B-27.63%+35.33%$166.5K+2.73%Sell Now
Mar 31, 2024SellBCRXHelen M. ThackrayChief R&D Officer7,525$5.08$2.1B-27.63%+35.33%$38.2K-3.01%Sell Now
Jan 3, 2024SellBCRXJon P StonehousePresident & CEO40,000$6.00$2.1B-27.63%+35.33%$240.0K+0.00%Sell Now
Dec 19, 2023SellBCRXAlane P BarnesChief Legal Officer2,482$6.05$2.1B-27.63%+35.33%$15.0K-0.84%Sell Now
Dec 19, 2023SellBCRXAnthony DoyleChief Financial Officer2,482$6.05$2.1B-27.63%+35.33%$15.0K-1.08%Sell Now
Dec 19, 2023SellBCRXCharles K GayerChief Commercial Officer2,482$6.05$2.1B-27.63%+35.33%$15.0K-0.90%Sell Now
Dec 19, 2023SellBCRXHelen M. ThackrayChief R&D Officer5,580$6.05$2.1B-27.63%+35.33%$33.8K-2.19%Sell Now
Dec 19, 2023SellBCRXJon P StonehousePresident & CEO14,089$6.05$2.1B-27.63%+35.33%$85.2K-1.25%Sell Now
Dec 14, 2023SellBCRXHelen M. ThackrayChief R&D Officer3,031$6.43$2.1B-27.63%+35.33%$19.5K-0.61%Sell Now
Dec 14, 2023SellBCRXAlane P BarnesChief Legal Officer4,015$6.43$2.1B-27.63%+35.33%$25.8K-0.88%Sell Now
Dec 14, 2023SellBCRXAnthony DoyleChief Financial Officer5,475$6.43$2.1B-27.63%+35.33%$35.2K-1.39%Sell Now
Dec 14, 2023SellBCRXCharles K GayerChief Commercial Officer5,840$6.43$2.1B-27.63%+35.33%$37.6K-1.32%Sell Now
Dec 14, 2023SellBCRXJon P StonehousePresident & CEO13,592$6.43$2.1B-27.63%+35.33%$87.4K-0.78%Sell Now